Evolus Inc (NASDAQ:EOLS) Short Interest Update

Evolus Inc (NASDAQ:EOLS) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 5,700,000 shares, a growth of 11.8% from the December 15th total of 5,100,000 shares. Based on an average daily trading volume, of 553,500 shares, the short-interest ratio is presently 10.3 days. Currently, 25.6% of the shares of the stock are short sold.

Several research firms recently issued reports on EOLS. Svb Leerink began coverage on shares of Evolus in a research report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective for the company. ValuEngine upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. Zacks Investment Research upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright restated a “buy” rating on shares of Evolus in a research report on Tuesday, November 5th. Finally, Leerink Swann began coverage on shares of Evolus in a research report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Evolus currently has an average rating of “Buy” and a consensus price target of $26.36.

In other news, insider Rui Avelar sold 39,442 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.71, for a total value of $422,423.82. Following the completion of the sale, the insider now directly owns 70,802 shares in the company, valued at $758,289.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.90% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY acquired a new stake in shares of Evolus during the third quarter valued at about $90,000. Millennium Management LLC increased its position in shares of Evolus by 36.7% during the third quarter. Millennium Management LLC now owns 170,072 shares of the company’s stock valued at $2,656,000 after acquiring an additional 45,653 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Evolus by 37.9% during the third quarter. California State Teachers Retirement System now owns 23,541 shares of the company’s stock valued at $368,000 after acquiring an additional 6,473 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of Evolus by 15.3% during the third quarter. Global Retirement Partners LLC now owns 23,070 shares of the company’s stock valued at $360,000 after acquiring an additional 3,063 shares during the last quarter. Finally, State Street Corp increased its position in shares of Evolus by 21.6% during the third quarter. State Street Corp now owns 230,987 shares of the company’s stock valued at $3,608,000 after acquiring an additional 41,046 shares during the last quarter. Institutional investors and hedge funds own 16.94% of the company’s stock.

Shares of EOLS traded up $0.28 during trading on Thursday, reaching $11.12. 9,188 shares of the company traded hands, compared to its average volume of 675,165. Evolus has a twelve month low of $10.31 and a twelve month high of $30.25. The stock has a market cap of $366.67 million, a PE ratio of -6.99 and a beta of 4.24. The stock has a 50-day simple moving average of $12.19 and a 200-day simple moving average of $14.93. The company has a quick ratio of 3.28, a current ratio of 3.66 and a debt-to-equity ratio of 4.53.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.55. The company had revenue of $13.17 million for the quarter, compared to analyst estimates of $5.18 million. On average, equities research analysts predict that Evolus will post -3.75 EPS for the current year.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: Bond

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.